Biotin-14-dATP
Invitrogen17万+抗体限时买二赠一,靶点广,灵活用!
Biotin-14-dATP
Invitrogen™

Biotin-14-dATP

Biotin-14-dATP is a patented dATP analog with biotin attached at the 6-position of the purine base by a 14-atom linker.Read more
Have Questions?
Catalog NumberQuantity
1952401650 nmol
Catalog number 19524016
Price (CNY)
8,055.00
Each
Add to cart
Quantity:
50 nmol
Price (CNY)
8,055.00
Each
Add to cart
Biotin-14-dATP is a patented dATP analog with biotin attached at the 6-position of the purine base by a 14-atom linker. The long, 14-atom spacer arm allows accessibility to streptavidin for sensitive detection of probe-target hybrids in in situ and filter-based hybridizations. Biotin-14-dATP can be efficiently incorporated into DNA by nick translation in the presence of dCTP, dGTP, and dTTP (1). Biotin-14-dATP can be added to the 3´ end of DNA using terminal deoxynucleotidyl transferase (2). The amount supplied is sufficient for labeling up to 50 μg of DNA by nick translation.

Performance and Quality Testing: Purity is evaluated by reverse-phase HPLC analysis.
For Research Use Only. Not for use in diagnostic procedures.
Specifications
FormatLiquid
Labeling MethodDirect Labeling
Product TypeLabeled Nucleotide
Quantity50 nmol
Shipping ConditionApproved for shipment on Wet or Dry Ice
Concentration0.4 mM
Label or DyeBiotin and Other Hapten
Unit SizeEach
Contents & Storage
Biotin-14-dATP is supplied at 0.4 mM in 100 mM Tris-HCl (pH 7.5), 0.1 mM EDTA. Store at -20°C.

Citations & References (1)

Citations & References
Abstract
Isolation and characterization of the human cytochrome P450 CYP1B1 gene.
Authors: Tang Y M; Wo Y Y; Stewart J; Hawkins A L; Griffin C A; Sutter T R; Greenlee W F;
Journal:J Biol Chem
PubMed ID:8910454
'Previously, we identified a novel human cytochrome P450 cDNA that is inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and represents the first member of a new subfamily designated cytochrome P4501B1 (CYP1B1; Sutter, T. R., Tang, Y. M., Hayes, C. L., Wo, Y. P., Jabs, E. W., Li, X., Yin, H., Cody, C. W., ... More